We report the long-term results of Tokyo Children's Cancer Study Group's studies L84-11, L89-12, L92-13, and L95-14 for 1846 children with acute lymphoblastic leukemia, which were conducted between 1984 and 1999. The value of event-free survival (EFS)±s.e. was 67.2±2.2% at 10 years in L84-11, which was not improved in the following two studies, and eventually improved to 75.0±1.8% at 10 years in L95-14 study. The lower EFS of the L89-12 reflected a high rate of induction failure because of infection and delayed remission in very high-risk patients. The L92-13 study was characterized by short maintenance therapy; it resulted in poor EFS, particularly in the standard-risk (SR) group and boys. Females did significantly better than males in EFS in the early three studies. The gender difference was not significant in overall survival, partly because 460% of the males survived after the testicular relapse. Randomized studies in the former three protocols revealed that intermediate-or high-dose methotrexate therapy significantly reduced the testicular relapse rate. In the L95-14 study, gender difference disappeared in EFS. Contrary to the results of larger-scale studies, the randomized control study in the L95-14 reconfirmed with updated data that dexamethasone 8 mg/m 2 had no advantage over prednisolone 60 mg/m 2 in the SR and intermediate-risk groups. Prophylactic cranial irradiation was assigned to 100, 80, 44, and 44% of the patients in the studies, respectively. Isolated central nervous system relapse rates decreased to o2% in the last two trials. Secondary brain tumors developed in 12 patients at 8-22 years after cranial irradiation. Improvement of the remission induction rates and the complete omission of irradiation are currently main objectives in our studies. Leukemia (2010) 24, 383-396; doi:10.1038/leu.2009 published online 24 December 2009 Keywords: acute lymphoblastic leukemia; children; long-term results; cranial irradiation; secondary malignancy
Introduction
We present here the long-term results of four studies for childhood acute lymphoblastic leukemia (ALL) of Tokyo Children's Cancer Study Group (TCCSG) conducted between 1984 and 1999.
Treatment protocol for SR and IR of the L84-11 study 1,2 was based on the early St Jude's total therapy. 3 ALL-BFM 81 4 protocol was modified and introduced to extremely high-risk group regimen for the first time. The protocols of the following three studies L89-12, 1,5 L92-13, 1, 6 and L95-14, 7 were designed on the basis of the ALL-BFM framework. All the four protocols contained trials to reduce the number of patients who received irradiation, as had been reported in other studies. 8, 9 The second point of analysis was on a gender difference [10] [11] [12] with respect to long-term event-free survival (EFS) and overall survival (OS). Randomized studies were mostly designed to test whether or not intermediate-dose methotrexate (ID-MTX) and high-dose methotrexate (HD-MTX) could replace the cranial irradiation. It is needed to describe the further long-term outcome of the patients who were treated in L92-13 study, which was characterized by very short maintenance therapy. We published the discordant results on the randomized comparison between dexamethasone and prednisolone in 2005, which was updated in this analysis. 7 
Materials and methods
Total of 1846 newly diagnosed patients with ALL aged 1-15 years entered into the four studiesFthat is L84-11 (n ¼ 484), L89-12 (n ¼ 418), L92-13 (n ¼ 347), and L95-14 (N ¼ 597)Fas shown in Table 1 . Diagnoses were made based on morphology, immunophenotype, and cytogenetics in each institution; the ALL committee evaluated these results for eligibility. Patients aged 1-6 years presented with a leukocyte count o20 Â 10 9 /l and B-precursor phenotype were classified into the standard-risk (SR) group in all the studies. Definitions of the intermediate-risk (IR) and high-risk (HR) or extremely high-risk groups varied across the four studies. Nonetheless, HR patients were mostly defined as having one of the following: initial leukocyte count X100 Â 10 9 /l, age of X10 years, leukocyte count X50 Â 10 9 /l; Philadelphia chromosome (Ph) or BCR-ABL fusion gene product positive, 11q23 chromosome translocation or MLL gene rearrangements, and T-ALL with otherwise IR-risk factors. The reminder of the SR and HR patients was assigned to the IR group. Analysis of the outcome was based on the risk classification of the NCI/Rome criteria. 13 Leukemic-cell karyotype was obtained from 20 to 30% of the patients in the first three studies. The DNA index was measured by flow cytometry.
Infants were excluded from these studies, and their treatment results were already published elsewhere.
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Treatment
The precise regimens of L84-11, 2 L89-12, 5 L92-13, 6 and L95-14 7 studies were available in earlier publications. Table 2 provides a summary of regimens in each study.
L84-11 study (1984) (1985) (1986) (1987) (1988) (1989) . Both the SR and HR groups were randomized at early intensification into two armsFthat is S1 and S2, and H1 and H2, respectively. In the S2 and H2 arms, the patients received three courses of ID-MTX (500 mg/m 2 ) with a single dose of leucovorin rescue (12 mg/m 2 ) at 48h, in conjunction with double-drug intrathecal injections (DIT) before cranial irradiation. In the S1and H1 arms, 18 Gy of cranial irradiation with five doses of triple-drug intrathecal injections (TIT) were administered without ID-MTX.
The DIT consisted of methotrexate (MTX) 15 mg/m 2 p15 mg and hydrocortisone 30 mg/m 2 p30 mg, respectively. The TIT consisted of DIT and cytosine arabinoside (CA) 30 mg/m 2 p30 mg.
L89-12 study (1989) (1990) (1991) (1992) . The regimen was based on the BFM backbone in all three risk groups. There was a week of prophase treatment with prednisolone alone to evaluate initial steroid response, as BFM group described. 17 The main objective was to determine whether cranial irradiation was essential to the treatment of SR patients or not. To do so, the SR patients were randomly assigned to the SR0 and SR18 arms, and patients in the SR0 arm were given three courses of HD-MTX (3 g/m 2 ) with three DIT without cranial irradiation. The doses of intrathecal injection were reduced from those of the earlier study, changing to age-adjusted calculation. The patients assigned to the SR18 arm received 18 Gy of cranial irradiation and three doses of TIT. The randomization ratio in SR arms changed from 1:1 to 2:1 in the last half period, so that there were 83 patients enrolled in SR0 arm and 64 in SR18 arm. The HR group was treated with a single arm of BFM-style therapy for 2 years, modified with an insertion of HD-MTX (3 g/m 2 , two courses) between the induction (Ia) and early intensification and cranial irradiation (Ib). Four courses of multiple-drug intensifications were given during the first year followed by 1-year maintenance therapy.
L92-13 study (1992-1994).
A major objective was to evaluate 1-year therapy in all risk groups. The length of the maintenance therapy was kept to a minimum of 6 months in the SR group and 3 months in each of the IR and HR groups. All three risk regimens had BFM-type structures. This protocol was characterized by the use of intermediate-dose cytosine arabinoside (ID-CA, 500 mg/m 2 /day for 4 days) and high-dose cytosine arabinoside (HD-CA, 1 or 2 g/m 2 /day for 4 days) in the early intensification and in the re-intensification phases.
The SR regimen had two courses of HD-MTX (3 g/m   2 ) and two DITs. The early intensification phases were complete before week 28; 24 weeks were left for the continuous therapy. IR group was randomized either to IR18 arm with 18-Gy cranial irradiation, or to IR0 arm with two courses of HD-MTX (3 g/m 2 / day) without cranial irradiation. All patients of the HR group were given 2 weekly courses of HD-CA (2 g/m 2 , six doses for 3 days) and mitoxantrone (2 days) after remission induction.
L95-14 study (1994) (1995) (1996) (1997) (1998) (1999) . SR and IR groups were randomized into prednisolone arm (PSL) and dexamethasone arm (DEX) not only in the induction, but also in re-induction phase and three courses of late intensification for SR and two courses for IR. During remission induction, prednisolone (60 mg/m 2 ) or dexamethasone (8 mg/m 2 ) was given for 4 weeks and tapered. In the re-induction and intensification courses, prednisolone (40 mg/m 2 ) or dexamethasone (6 mg/m 2 ) were given for 2 weeks in each arm. For patients presenting with leukocyte count X150 Â 10 9 /l and aged 7 years or older (assigned to allo-stem-cell transplantation (SCT) group), allogeneic bone marrow transplantation from HLA-matched family donor, if any, and autologous blood or marrow SCT or chemotherapy could be elected. For patients presented with Table 1 Event-free survival, overall survival, and CNS relapse of TCCSG studies L84-11, L89-12, L92-13, and L95-14 Abbreviations: CNS, central nervous system; s.e., standard error; TCCSG, Tokyo Children's Cancer Study Group. a Corrected remission (rate %): patients who achieved delayed remission were included in remission, and censored patients during the induction phase were excluded from the total.
Long-term results of ALL in TCCG M Tsuchida et al Number after drug-dose, (Numer), repeat. Randomizations were written with bold letters. Randomized*, initially randomized for whole course. **Proportion of the patients who were initially assigned to cranial irradiation arm; actual proportion was lower than the assigned.
Long-term results of ALL in TCCG M Tsuchida et al leukocyte count X100 Â 10 9 /l, or 10 years old or older with leukocyte count X50 Â 10 9 /l (assigned to auto-SCT group), autologous blood or marrow SCT or chemotherapy could be elected. Each institute declared the choice in advance of the study initiation.
Statistical analysis
The duration of EFS was defined as the time from the initiation of therapy to the date of failure (that is any relapse, death, or diagnosis of secondary malignancy) or to the date when patients were confirmed to be in remission and alive. Patients who did not achieve complete remission at the end of the initial induction phase or who died before the confirmation of remission were considered to have failed at day 0, even if they entered remission later with a second course or through additional treatment. The probability of EFS and s.e. was estimated by the Kaplan-Meier method (Greenwood), and differences were tested by the log-rank test. Analysis was performed with the intent to treat. 'Any central nervous system (CNS) relapse' include both 'isolated CNS relapse' and CNS relapse combined with other sites. Probability of cumulative CNS relapse was estimated by inversed Kaplan-Meier method, which involves subtraction of Kaplan-Meier products from 100%. Only patients who had CNS relapse were failure, and all the others were censored. Cumulative probability of any secondary malignancy was calculated using the same method. Patients who received modified treatment were censored at that point in time. The patients who did not enter complete remission or had died during induction were treated as at the date of the beginning of treatment. Patients who were confirmed as remaining in first remission and alive, or who were lost of follow-up, were censored for EFS analysis; all those who were alive with or without disease were censored in OS analysis at the date of last contact.
Follow-up was updated in 2008. The proportions of patients whose data of the last 5 years were available were 144 of 357 (40.3%) in L84-11 study, 197 of 306 (64.3%) in L89-12, 220 of 266 (82.7%) in L92-13, and 449 of 489 (91.8%) in L95-14.
Results
Probability of EFS, OS, and cumulative CNS relapse rate of each study are shown in Tables 1 and 3 . There was no improvement in EFS during the first three studies. The OS of L92-13 improved, Table 3 Summary of the study results Long-term results of ALL in TCCG M Tsuchida et al compared with these of the earlier two studies. The L95-14 study achieved internationally acceptable level of EFS and OS (logrank Po0.0001). The cumulative 'any CNS relapse' rate decreased from 5.5% (any CNS) in the L84-11 study to 2.8% in the L95-14 study. Twelve treatment-related brain tumors developed in patients who had received cranial irradiation in the four studiesFthat is 5, 4, 2, and 1 patient, respectively. They developed in six males and six females. No brain tumor occurred in the non-irradiated patients. The tumors developed between 8 and 22 years after cranial irradiation, seven in the 18-Gy irradiated group and five in the 24-Gy irradiated group. The probability of cumulative incidence ( ± s.e.) of brain tumors was 1.9 ± 0.6% at 15 years and 2.8±0.9% at 20 years among the 1234 irradiated patients. Secondary acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS) developed in eight patientsFthat is 0/1, 3/1, 0, and 2/1 in each study. Two of them (L89-12) were confirmed to have 11q23 chromosome abnormality. Seven of the eight patients were female, whereas brain tumors developed evenly in terms of gender. AML/MDS occurred only in the irradiated patients without exception. The probability of cumulative incidence±s.e. of AML/MDS among irradiated patients was 0.57 ± 0.25% at 3 years and 1.1 ± 0.4% at 10 years.
Studies
Cerebrovasucular lesions such as Moyamoya disease developed after radiation in the TCCSG studies and published elsewhere. 18 Neurocognitive evaluation study was not carried out as a group.
Protocol-specific treatment result L84-11 study. For 484 patients enrolled, EFS±s.e. and OS ± s.e. were 66.3 ± 2.2 and 73.5 ± 2.1% at 15 years, respectively. There were 357 long-term survivors, and their median follow-up period was 16.6 years. Among survivors, seven had serious neurological sequelae, such as paraparesis or leukoencephalopathy, which developed most probably because of cranial irradiation and concentrated use of five TITs at bodysurface-adjusted dose setting. Probability of cumulative incidence of brain tumors in L84-11 was 1.2±0.7% at 15 years (Tables 3 and 4 ; Figure 1 ).
Males fared significantly worse than females in terms of EFS (Table 4 ; P ¼ 0.006), but not in terms of OS (P ¼ 0.205). Isolated or combined testicular relapses developed in 27 out of 261 males (10.3%) and they comprised 22% of all relapses.
As a result of the randomized comparison in SR, the EFS ± s.e. rates of the S1 and S2 arms were 68.5±4.8 and 81.0±4.1%, respectively, at 15 years (log-rank test, P ¼ 0.071). The probabilities of cumulative incidence ±s.e. of any testicular relapse were 24.3 ± 6.7% in S1 arm and 4.7 ± 3.3% in S2 arm (log-rank P ¼ 0.015).
L89-12 study. For the 418 patients enrolled, the EFS ± s.e. and OS rate were 62.3±2.6 and 71.9±2.2% at 1 year, respectively. Probability of cumulative isolated CNS and any Table 4 Treatment results according to presenting features in non-infant patients treated in study L84-11 Long-term results of ALL in TCCG M Tsuchida et al CNS relapse rates were 3.7 ± 1.1 and 5.4 ± 1.3% at 15 years, respectively. Of the 306 surviving patients, the median survival period was 14.6 years. Secondary neoplasms consisted of four brain tumors, three AML, and one MDS. Remission induction rate was 92.8%, which was the lowest of the four studies (Table 3) . Twelve patients (2.9%) died during or after the remission induction course, between days 10 and 82. The major cause of death was prolonged marrow suppression and infection. Of 17 patients (4.1%) failed to enter remission at the end of induction, six patients (1.4%) died within 4-24 months; one Ph positive ALL, and four with leukocyte count 4145 Â 10 9 /l. The other 11 patients entered remission in the following phase; five patients with leukocyte counts 4100 Â 10 9 /l, seven Ph positive ALL. The corrected remission rate was 95.7% when the patients who entered into delayed remission were included in remission and those who were dropped off during induction were excluded from the total number. Pirarubicin used for induction at a dosage of 30 mg/m 2 (two or three doses) was amended to 20 mg/m 2 in October 1990. Nine out of 12 deaths occurred before the amendment. Testicular relapse was significantly fewer in incidence in SR0 (HD-MTX) arm than the SR18 arm (P ¼ 0.018; Tables 3, 5; Figure 2 ). L92-13 study. EFS±s.e. and OS±s.e. for 347 eligible patients enrolled were 60.1 ± 2.7 and 77.9 ± 2.2% at 10 years, respectively. Cumulative rate of isolated CNS relapse was 1.0 ± 1.0 at 10 years, which might be underestimated by high bone marrow relapse rate. The median follow-up period was 13.0 years for the 271 (78.1%) patients remaining alive, including 64 patients who experienced relapse. Twenty-one HR patients underwent hematopoietic SCT at first remission (treated as censored), and 18 were alive in CR (Tables 3, 6 ; Figure 3 ).
Brain tumors occurred in two patients. No myeloid leukemia or MDS developed. The rate of remission induction was 96.0%.
Seven of 26 relapses among 62 males in SR group relapsed very late at 5-13 years of the initial therapy, whereas females stopped recurring at 5 years. Overall, the EFS in males was 47.5 ± 4.3% at 15 years, which was significantly lower than that in females (68.0 ± 3.8%, P ¼ 0.0003). Males were, however, more efficiently salvaged. The OS of males was 75.8 ± 3.3% and that of females 80.3±3.1% (P ¼ 0.731; Table 6 ). Ten of 14 patients with isolated or combined testicular survived. After relapse, 51 patients survived out of 84 who had undergone hematopoietic SCT (actual survival 60.7%). Of 25 who had been treated with chemotherapy, 15 survived after relapse (60%). The OS rate of 77.4 ± 2.4% eventually exceeded the preceding two studies.
L95-14 study. L95-14 study achieved 5-year EFS±s.e 75.0 ± 1.8% and the OS ± s.e. 82.0 ± 1.6%, at 10 years' follow-up. For the 489 patients who remained alive, the median follow-up period was 10.0 years. The remission induction rate after the initial course was 95.0%. The corrected remission induction rate was 97.5% when nine patients who were off during induction were excluded and six patients who entered into remission in the following phase were included. The cumulative isolated CNS relapse rate was 1.7 ± 0.6% and 'any CNS relapse' rates was 2.8±0.7% for all patients, and the latter level was 4.3 ± 1.4% in the HR. One brain tumor occurred at 8.3 years, two AML, and one MDS all were diagnosed between 1.5 and 5.2 years of therapy (Tables 3, 7; Figures 4) .
The results of randomized control study was updated and showed again no advantage of DEX arm over PSL arm in SR and IR groups 7 (Tables 2, 7) . Three extramedullary relapses occurred in the DEX arm, whereas eight developed in the PSL arm.
Hematopoietic SCTs, either allogeneic or autologous blood and marrow source, were elected by institutional intention to Long-term results of ALL in TCCG M Tsuchida et al treat decision in advance and executed for 61 (37 allo-SCT and 24 auto-SCT) of 126 patients who assigned to SCT (59 allo-SCT and 67 auto-SCT), among which 44 (actual rate72.1%) were alive without relapse. Of the 65 patients who assigned to SCT group, but elected chemotherapy, 30 (46, 2%) patients were alive; 29 were in first remission.
Treatment results according to presenting features
Well-documented prognostic factors were analyzed in each of the four studies (Tables 4-7) . Infants were not included in these studies. Patients with B-precursor ALL and T-ALL were analyzed separately in each of the four studies, according to the NCI / Rome criteria. Age and leukocyte count at diagnosis were still independently strong prognostic factors. Patients with T-ALL had poor prognosis. This was more evident in terms of OS (Tables 2-5) . Clearly, patients with T-ALL could not be easily salvaged after relapse. Females fared significantly better than males in terms of EFS at 10 years by 13.2 points (L84-11, P ¼ 0.006), 11.0 points (L89-12, P ¼ 0.044), 15.6 points (L92-13, P ¼ 0.003), and -2.8 points (L95-14, males fared better, P ¼ 0.519), respectively (Table 3) . 'Any testicular relapse' rate was 10.3, 5.8, 8.5, and 2.4% of all the males in the four studies, respectively ( Table 3 ). The cumulative incidence of testicular relapse was significantly lower in ID-MTX or HD-MTX arms in randomized trials of the L84-11 SR, L89-12 IR, and L92-13 IR, as has been described. 19 The gender difference in EFS correlated well with the incidence of testicular relapse. Approximately 60% of the patients with any testicular relapse survived and contributed to the recovery of male OS to the same level as females. CNS involvement at presentation had negative prognostic impact on EFS (Tables 4 and 5 ). In L95-14 study (Table 7) , patients who presented with DNA index of 1.16-1.60 showed EFS 84.2 ± 3.5%, which was significantly higher than the EFS rate of 72.3±2.2% among those with DNA indexo1.16 (P ¼ 0.005). 20 DNA index 1.16-1.60 group of patients also fared better than those with DNA index over 1.6 (EFS of 50.0±17.7%, P ¼ 0.003).The outcome of the patients with Ph chromosome was dismal. Hematopoietic SCT was only curative treatment strategy so far. 21 
Table 5
Treatment results according to presenting features in non-infant patients treated in study L89-12 
Long-term results of ALL in TCCG M Tsuchida et al
Discussion
Nine years passed since the earlier issue was published in 'Leukemia 2000.' 1 The 1423 survivors in the four studies are now 22.5 years old on an average, ranging from 11.6 to 39.8 years of age. Of 1233 patients who received cranial irradiation, 873 were surviving. Twelve secondary brain tumors developed very late, that is at 8-22 years after initial therapy including cranial irradiation in the four studies presented here. The development of the brain tumors seemed not to depend on the studies. Hijiya et al. 22 reported from the St Jude that the cumulative incidence of brain tumor except for meningioma was 3.00±0.59% at 30 years. It was 2.8±0.9% at 20 years in the four studies.
As for the secondary AML/MDS, the incidence was variable depending on the study. They developed only in the irradiated patients without exception. Regimens of L89-12 and L92-13 studies included etoposide, which is a topo-II inhibitor and was highly associated with the development of secondary MAL/MDS with 11q23 chromosome translocations. 23, 24 Two cases were confirmed to be associated with chromosome 11q23 translocations in L89-12 study. It was noteworthy that seven out of eight secondary AML/MDS patients were female, whereas the brain tumors developed equally across genders. It was described that girls were more sensitive to anthracycline cardiac toxicity than boys. 25 In addition, cognitive impairment, short stature, and excessive weight were all more prevalent among females than males. 26 Females responded more to the chemotherapy and remained in higher EFS than that of males. All these facts may suggest that girls are more sensitive to anti-leukemic drugs, resulting in better outcome of ALL and developed more therapy-related secondary AML/MDS. Schmiegelow recently reported from NOPHO studies that children with low thiopurine methyltransferase activity were at lower risk of relapse of ALL 27 and were at higher risk of developing secondary malignancy. 28 In the latter article, of 20 secondary malignancies, 16 AML/MDS occurred in 6 males and 10 females, although the author did not mention the gender difference.
We had not performed neurocognitive assessment as a group, but many studies showed the negative influence of the cranial irradiation on the neurocognitive function particularly for the young patients, 26 and other study described that normal neurological function was preserved when irradiation was omitted. 29 In the next study of TCCSG ALL L99-15, irradiated patients were limited to o10%. In the currently active study, T-ALL and prednisolone poor responders were irradiated. The outcomes have already been reported on the protocols with no cranial irradiation from St Jude Children's Research Hospital, 30 EORTC, 31 Nordic countries, 32 and Netherlands. 33 To eliminate the cranial irradiation, the function of intrathecal injections would be expected. The 9-11 times intrathecal injections ended before 40 weeks in TCCSG protocols even when no cranial irradiation was administered. The proper number and timing of the extended intrathecal injections for patients at risk of CNS relapse such as hyper-leukocytosis and T-ALL remained to be determined in our future studies.
Gajjar et al. 34 express strong caution to traumatic lumber punctures as a risk factor of CNS relapse. The L89-12 and L92-13 studies had 1-week prophase of single therapy with oral prednisolone, and the initial intrathecal injection and cerebrospinal fluid examination was given on day 8. 5, 35 The prednisolone prophase without spinal puncture might well have alleviated cerebrospinal fluid infiltration before the assessment. Consequently, initial ratio of patients with CNS-2 or CNS-3 was Long-term results of ALL in TCCG M Tsuchida et al Table 6 Treatment results according to presenting features in non-infant patients treated in study L92-13 Long-term results of ALL in TCCG M Tsuchida et al lower on day 8 in our studies than that on day 1 of other studies. It has been shown that the day 8 puncture did not increase CNS relapse. 5 The initial day 8 lumbar puncture is a safe method to avoid inadvertent introduction of leukemic blasts into the cerebrospinal fluid.
The duration of the maintenance therapy had been shortened step by step from 4 years in L81-10 study, 3 years for SR in L84-11 study, and 1.5 years for SR and 1 year for HR in L89-12 study without increasing relapses. The ID-MTX in S2 arm of L84-11 study efficiently reduced relapse after off therapy, whereas the control arm showed clusters of relapse starting at the point of off therapy. These results developed a hypothesis that an addition of a new intensified treatment on early phase might make it possible to shorten the duration of therapy further without sacrificing overall outcome. Randomized study could not be realized because a control arm was difficult to set. For the intensification of early therapy, ID-CA and HD-CA and mitoxantrone were administered in all risk groups. As a result, the relapse increased in both SR and HR groups. The short maintenance therapy affected more negatively on the lower-risk patients and males than on the higher risk and females (Table 6) . EFS of HR patients was almost equivalent to that of SR. The early intensification might be more effective in HR than SR as CCG reported. 36 Randomized comparison of length in maintenance therapy for 18 months vs 24 months came to conclusion in ALL-BFM 81 4 and 83 37 studies, and ALL-BFM 86 38 study was amended to extend all the maintenance from 18 to 24 months. The appropriate length of maintenance therapy must be essential, particularly for the lower-risk patients and males. The duration between 18 months and 24 months were needed in the protocols of BFM-type structure. The boys had a higher risk of late relapse without sufficient maintenance therapy.
In 95-14, the randomized study in SR and IR compared between prednisolone (60 mg/m 2 at induction and 40 mg/m 2 at intensifications) and dexamethasone (8 mg/m 2 at induction and 6 mg/m 2 at intensifications) resulted in no significant difference in EFS rate. 7 Analysis with updated data on this comparison resulted in the same conclusion. Our results did not fully accord with those of other larger-scale studies. The results of CCG-1922 study 39 showed significantly better outcome in SR patients treated with dexamethasone at 6 mg/m 2 than prednisolone 40 mg/m 2 . In UK Medical Research Council ALL97 trial, 40 dexamethasone given at 6.5 mg/m 2 and prednisolone given at 40 mg/m 2 were compared, and the dexamethasone arm showed better outcome. A conclusive result is anticipated in the trials with higher dose of dexamethasone at 10 mg/m 2 along with the evaluation of side effects.
In conclusion, analysis of long-term follow-up results brought us invaluable suggestions to consider for our future studies. Girls may generally be more drug sensitive than boys and they could be cured with shorter maintenance therapy than boys; at the same time, they may be at higher risk of secondary AML/MDS. The testicular relapse and lower EFS in boys were almost resolved in L95-14. TCCSG currently limited the indication of cranial irradiation to o10% of the patients. To avoid the secondary malignancy and neurological sequelae, it is of primary importance to omit the cranial irradiation and the etoposide completely as a primary therapy. Safe and effective induction and immediately given intensification, as well as appropriate length of maintenance therapy, are still major subjects to study. We seriously realized that an establishment of firm long-term follow-up system is mandatory to evaluate the ultimate result of the protocols. Long-term results of ALL in TCCG M Tsuchida et al Table 7 Treatment results according to presenting features in non-infant patients treated in study L95-14 Long-term results of ALL in TCCG M Tsuchida et al
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